

Edgar Filing: TUTOGEN MEDICAL INC - Form SC 13D/A

TUTOGEN MEDICAL INC  
Form SC 13D/A  
March 22, 2004

Securities and Exchange Commission,  
Washington, D.C. 20549  
Schedule 13D/A

Under the Securities Exchange Act of 1934  
(Amendment No. 7)

TUTOGEN MEDICAL, INC.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

901 107 10 2  
(CUSIP Number)

Thomas W. Pauken, Liquidating Trustee  
Capital Partners II, Ltd. Liquidating Trust  
(successor to Renaissance Capital Partners II, Ltd.)  
5646 Milton Street, Suite 900  
Dallas, Texas 75206  
(214) 378-9340

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

March 19, 2004  
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

NOTE: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See section 240.13d-7(b) for other parties to whom copies are to be sent.

CUSIP No. 901 107 10 2

- (1) Names of reporting persons  
I.R.S. Identification Nos. of above persons (entities only)  
Capital Partners II, Ltd. Liquidating Trust 75-6590369
- (2) Check the appropriate box if a member of a group [ ]
- (3) SEC use only
- (4) Source of funds  
OO
- (5) Check if disclosure of legal proceedings is required pursuant to  
Items 2(d) or 2(e) [ ]
- (6) Citizenship or place of organization

Edgar Filing: TUTOGEN MEDICAL INC - Form SC 13D/A

Texas

Number of shares beneficially owned by each reporting person with:

(7) Sole voting power

2,975,139

(8) Shared voting power

0

(9) Sole dispositive power

2,975,139

(10) Shared dispositive power

0

(11) Aggregate amount beneficially owned by each reporting person

2,975,139

(12) Check if the aggregate amount in Row (11) excludes certain shares  
[ ]

(13) Percent of class represented by amount in Row (11)

18.91%

(14) Type of reporting person

00

Item 1. Security and Issuer

The Schedule 13D filed by Renaissance Capital Partners II, Ltd. on February 10, 1999 with respect to securities of Tutogen Medical, Inc., as previously amended, is hereby further amended as set forth in this Amendment No. 7. Except as amended herein, the disclosure contained in the original Schedule 13D, as amended, remains in effect. Capitalized terms used but not defined herein shall have the meanings ascribed in the original Schedule 13D.

Item 3. Source and Amount of Funds or Other Consideration

These Amendment No. 7 does not report the acquisition of any additional securities.

Item 4. Purpose of Transaction

The Trust was organized for the purpose of conducting an orderly liquidation of the assets of Renaissance Capital Partners II, Ltd. and had an initial term of two years, ending on November 17, 2002.

As previously reported, the Trustee extended the term of the Trust an additional year, until November 17, 2004, and he also permitted the beneficiaries of the Trust to withdraw from the Trust, and have distributed to

Edgar Filing: TUTOGEN MEDICAL INC - Form SC 13D/A

them their pro rated shares of Tutogen common stock then held by the Trust.

As a result of the elections made by beneficiaries, on March 19, 2004, the Trust began distributing 649,787 shares of Tutogen common stock, representing the pro rata interests of beneficiaries who elected to withdraw from the Trust. The Trust continues to own 2,975,139 shares of Tutogen common stock after deducting all of the shares being distributed to withdrawing beneficiaries.

Item 7. Material to be Filed as Exhibits.

None.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 19, 2004

CAPITAL PARTNERS II, LTD.  
LIQUIDATING TRUST

By: /s/  
Thomas W. Pauken  
Liquidating Trustee